Page 1

CENTESSA TM PHARMACEUTICALS Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates August 16 , 2021 ~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $ 379.5 million to help advance portfolio of 16 clinical and preclinical programs ~ ~ Centessa leadership team strengthened through appointment of key industry executives ~ ~ Programs across Centessa portfolio continue to progress , with new data releases and / or trial initiations anticipated from ApcinteX , Palladio , Z Factor and Pega - One in the second half of 2021 ~ CAMBRIDGE , Mass . and LONDON , Aug. 16 , 2021 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq : CNTA ) , a clinical - stage company leveraging its innovative asset - centric business model to discover , develop and ultimately deliver impactful medicines to patients , today reported financial results for the quarter ended June 30 , 2021 , and provided a review of recent accomplishments and anticipated upcoming milestones . " Centessa has made significant progress since launch and completion of our $ 250 million Series A financing in January , " said Saurabh Saha , M.D. , Ph.D. , Chief Executive Officer of Centessa . " The successful execution of our upsized initial public offering in the second quarter has substantially enhanced our resources and will support the advancement of our broad portfolio of assets across our 10 subsidiary companies . This added capital , together with the appointment of exceptional industry leaders in key functional areas across the organization , positions us for continued success . We look forward to sharing our progress , including a planned Phase 2a data update from ApcinteX in the coming weeks . " Business Updates • $ 379.5 Million Initial Public Offering ( IPO ) Successfully Completed : In the second quarter , Centessa closed its initial public offering of 16,500,000 American Depositary Shares ( ADSs ) . In addition , the underwriters fully exercised their option to purchase an additional 2,475,000 ADSS at the IPO price of $ 20.00 per ADS , less underwriting discounts and commissions . The gross proceeds to Centessa from its IPO , before deducting underwriting discounts , commissions and other estimated offering expenses , totaled an aggregate of $ 379.5 million . • Leadership Team Strengthened by Appointment of Key Industry Executives : In May , Centessa announced the leadership appointments of Antoine Yver , M.D. , M.Sc. , Chief Medical Officer ; Tia Bush , Chief Quality Officer ; David Chao , Ph.D. , Chief Administrative Officer ; and Thomas Templeman , Ph.D. , Chief Technology Officer . In addition , Marella Thorell was promoted to Chief Accounting Officer , and Carol Stuckley joined the Board of Directors , serving as Chairperson of the Audit Committee . Each of these leaders provides significant expertise in their respective functions and will help drive execution across the Company's portfolio of programs . Program Updates and Upcoming Milestones in the Second Half of 2021 • Topline Phase 2a data from ApcinteX's 24 - week repeat dose study evaluating SerpinPC in hemophilia A ( HA ) and hemophilia B ( HB ) patients • SerpinPC , a first - in - class coagulation rebalancing agent , is a specific inhibitor of activated protein C ( APC ) being evaluated as a monthly subcutaneous therapeutic for HA and HB patients that has the potential to significantly reduce bleeding rates . • ⚫ The Phase 2a has completed dosing and the Company anticipates sharing topline results in the third quarter of 2021 . • All subjects who have completed the 24 - week repeat dose portion of the study have elected to roll - over into a long - term open - label extension study . • Start - up activities have begun for the ACTION Study , Palladio Biosciences ' global Phase 3 registrational study of lixivaptan in autosomal dominant polycystic kidney disease ( ADPKD ) • Lixivaptan , a vasopressin V2 receptor antagonist , is being investigated as a potential best - in - class therapy in patients with ADPKD . • The Company anticipates dosing the first patient in the registrational ACTION Study in the first quarter of 2022 . • The Company expects to report ongoing safety data from the initial subjects in the open - label ALERT Study of patients who previously discontinued JYNARQUE® ( tolvaptan ) due to liver toxicity in the fourth quarter of 2021 . • Phase 1 data from Z Factor's study evaluating ZF874 for the treatment of alpha - 1 - antitrypsin deficiency ( AATD )